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Abstract
Background—Injury to peritubular capillaries and capillary basement membrane
multilamination (PTCL) is a hallmark of antibody-mediated chronic renal allograft rejection.
However, the predictive diagnostic value of PTCL is incompletely studied.
Methods—We analyzed the diagnostic significance of PTCL and propose diagnostic strategies.
We evaluated 360 diagnostic native and 187 transplant kidney specimens by electron microscopy
(terminology: PTCL-C, severe; PTCL subgroup C3, very severe multilamination; see Materials
and Methods for definitions).
Results—PTCL was not pathognomonic for any specific disease. PTCL- C/C3 was rare in native
kidneys (C, 6%; C3, 1 %), associated mainly with late thrombotic microangiopathy (C: 78%; C3:
11% of cases). In allografts, PTCL-C/C3 was significantly more common, especially in specimens
more than 24 months after transplantation (C, 47%; C3, 31%). PTCL-C/C3 was found in acute (C,
20%; C3, 7%) and chronic T-cell rejection (C, 67%; C3,29%), calcineurin inhibitor toxicity (C,
36%; C3, 18%), or C4d+ specimens (C, 61%; C3, 50%) with odds ratios between 4 and 36. PTCL-
C3 was more predominant in cases with antibody-mediated injury. Highest odds ratios (81–117)
for PTCL-C/C3 were noted in combined injuries, that is, mixed chronic T-cell and concurrent
chronic antibody–mediated rejection. Positive predictive values of PTCL-C and C3 are the
following: all rejection types, 89% and 93%; all Banff chronic rejection types, 69% and 71%; and
chronic presumptive antibody rejection, 37% and 49%, respectively. Corresponding negative
predictive values of C and C3 for different Banff rejection categories are between 50% and 94%.
Conclusions—The presence of PTCL-C3 is a helpful adjunct finding to diagnose rejection-
induced tissue injury but cannot precisely predict the Banff rejection category. Conversely, the
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absence of PTCL-C3 is helpful in excluding chronic, Banff category II antibody-mediated
rejection.
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The diagnosis and classification of kidney allograft rejection depends heavily on changes
seen by light microscopy. Ultrastructural lesions are not specifically detailed in the “Banff
classification scheme,” and electron microscopy (EM) is only infrequently performed during
the systematic evaluation of graft biopsies. EM can, however, show intriguing abnormalities,
including glomerular capillary wall remodeling and peritubular capillary basement
membrane multilaminations (PTCL) that are interpreted by some as signs of chronic
antibody-mediated injury (1, 2).
Following the seminal descriptions by Monga et al. (3,4), subsequently Drachenberg et al.
(5), Ivanyi et al. (6), and Gough et al. (1) further reported on PTCL. Unfortunately, nearly
all studies on PTCL are limited by selected case series, lack of comparable scoring criteria
or comparative data from native kidneys, and occasionally even lack of EM as an
investigative tool (3, 7–12). In renal allografts, studies primarily focused on targeted
correlations between PTCL and specific morphologic changes, such as transplant
glomerulopathy (TGL) (1, 3–5, 7, 11, 13, 14) or C4d staining (8,9,11).
Our current EM-based study in for-cause renal specimens aims to define the diagnostic
significance of PTCL in renal allografts by evaluating a large cohort of native and kidney
transplant specimens. In a unique approach, we analyzed the relationship of PTCL to
histologic changes, disease categories, selected demographic and laboratory parameters, and
calculated odds ratios (ORs). We determined positive and negative predictive values of the
most severe forms of PTCL for “Banff rejection categories.” We suggest guidelines for the
incorporation of PTCL into the diagnostic evaluation of kidney transplant biopsies.
RESULTS
Forty-eight percent (265) of 547 specimens showed only circumferential multilayering in the
three capillaries scored, 5% (26) revealed only segmental multilayering, and 47% (256)
demonstrated a combination of segmental and circumferential laminations. Seventeen
percent (90) of 547 specimens showed intracase variations of three or more basement
membrane layers when comparing the most affected to the least affected capillary.
Interobserver Reproducibility
Two observers re-evaluated 150 capillaries to determine the reproducibility of PTCL counts.
Unweighted κ Cohen statistics showed good agreement levels of 0.66 for observer 1 (95%
confidence interval, 0.48 and 0.84) and 0.73 for observer 2 (95% confidence interval, 0.57
and 0.89) between original and PTCL recounts.
Native Kidneys
PTCL-A was found in 274 (76%) of 360 cases; PTCL-B, 63 (18%) of 360; PTCL-C, 23
(6%) of 360 (C1, 6 of 23 [26%]; C2, 13 of 23 [57%]; C3, 4 of 23 [17%]).
A. PTCL and patient demographics. PTCL group distributions were not significantly
associated with age, race, or sex.
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B. PTCL and disease categories (diabetes mellitus, arterionephrosclerosis, focal and
segmental glomerulosclerosis, various immune complex-mediated
glomerulonephritides, thrombotic microangiopathies [TMAs], ANCA-associated
vascu-litides, acute tubular injury, pyelonephritis, and end-stage renal diseases). In
native kidney specimens, PTCL-C was a rare finding (overall, 6%) with the
exception of TMAs, in particular the late disease stages, which demonstrated a
significantly higher prevalence of PTCL-C (14% in early and 78% in late TMA
phases). PTCL-C3 was highly uncommon in all native disease categories (1%).
C. PTCL and selected morphologic changes. Advanced sclerotic changes grade II
(global glomerulosclerosis, interstitial fibrosis/tubular atrophy, and arteriosclerosis
and arteriolosclerosis) correlated significantly with PTCL-C (prevalence of PTCL-
C in chronic changes grade I vs. grade II, 1%–4% vs. 10%–14%, respectively; all
differences P<0.05) but not with subgroup PTCL-C3. No significant correlations
were found between inflammatory changes, capillaritis, or endothelial cell
activation and PTCL-C/C3.
Kidney Allografts
PTCL-A was found in 72 (38%) of 187 cases; PTCL-B, 48 (26%) of 187; PTCL-C, 67
(36%) of 187 (C1, 14 [21%] of 67; C2, 10 [15%] of 67; C3, 43 [64%] of 67).
In comparison with native specimens, transplants showed a right shift with significantly
fewer cases in PTCL-A (P<0.001) and more in PTCL-B, C, and subgroup C3 (P<0.05,
P<0.001, and P<0.01, respectively). The overall prevalence of PTCL-C of 36% in
transplants was only paralleled in one native disease category: TMA (39% with PTCL-C,
difference from transplant group not significant). Compared with native kidneys, PTCL-C
and subgroup C3 were most typical for changes in allografts; therefore, these groups were
used for subsequent statistical analyses.
Time of Biopsy After Transplantation
The degree of severe PTCL-C increased after transplantation: 5% (C3, 0%) at year 1, 29%
(C3, 18%) at year 2, 36% (C3, 14%) at year 3, and 61% (C3, 48%) at more than 10 years.
Histologic Changes
Marked PTCL was significantly more common in cases with peritubular capillaritis grade II
versus grade I (PTCL-C, 57% vs. 14%; PTCL-C3, 38% vs. 6%; P<0.0001). Ultrastructural
capillaritis and endothelial cell activation correlated with PTCL-C (P<0.05) but not PTCL-
C3. Grade II versus grade I sclerotic changes (global glomerulosclerosis and interstitial
fibrosis/tubular atrophy) correlated significantly with PTCL-C and C3 (all P<0.05).
In comparison with early biopsies obtained during the first 12 months, PTCL-C/C3
increased significantly in specimens obtained after year 1 (P=0.001). Severe PTCL was most
prevalent in late biopsies with transplant glomerulopathy glomerulitis, C4d positivity, or
transplant sclerosing vasculopathy. With the exception of recurrent diabetic nephropathy,
marked PTCL was overall significantly less frequent in the comparative transplant control
group (40/64 biopsies taken >1 year after grafting; PTCL-C, 5% ; and PTCL-C3, 2%) (Table
1).
Transplant Glomerulopathy
At time of initial biopsy diagnosis of TGL, 65% of biopsies showed PTCL-C; and 53%, C3.
Marked PTCL was significantly more common in C4d+ (C, 81%; C3, 71%) compared with
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C4d− (C, 47%; C3, 32%; P<0.05) and in global (C, 77%; C3, 63%) compared with
segmental TGL (C, 30%; C3, 20%; P<0.03).
TGL is a morphologic phenotype caused by glomerular capillary injury of different
etiologies (15, 16). In a sub-analysis, we grouped TGL according to the presumptive
underlying cause. Comparing rejection with nonrejection-induced TGL, all rejection cases,
whether presumably cell or antibody mediated, were significantly more often global (84%
vs. 44% in nonrejection TGL, P<0.03) than segmental. Rejection-associated TGL was more
often associated with marked PTCL (C, 77%; C3, 65%) than nonrejection TGL (C, 22%;
C3, 11%; P<0.01).
Diagnostic Categories
a. Biopsy-based approach. Table 2 groups all 183 biopsies with C4d data according to
diagnostic categories (for diagnostic group I-IX definitions, see Table 2). Acute
rejection defined as diagnostic groups I to III: PTCL-C in 20% to 44% of biopsies
with either cellular or presumptive antibody-mediated rejection, PTCL-C3 in 7% to
33% (all differences for PTCL-C not significant). Chronic active rejection IV to VI:
PTCL-C in 67% to 79% of biopsies with either cell or presumptive antibody–
mediated chronic rejection (all differences not significant), PTCL-C3 in 29% (IV)
to 67% (VI) (difference between IV and combined V VI, P<0.02). Chronic active
IV to VI versus chronic inactive VII rejection: PTCL-C/C3 significantly more
frequent in the combined chronic active (C, 73%; C3, 49%) than chronic inactive
rejection groups (C, 38%; C3, 15%; P<0.04). Acute I to III versus corresponding
chronic IV to VII rejection groups: less PTCL in combined acute groups (C, 33%;
C3, 23%) than in combined chronic groups (C, 66%; C3, 43%; P=0.001 and
P<0.04, respectively). Pronounced differences between group I (acute cellular) and
IV (chronic active cellular rejection C, 20% vs. 67%, P=0.008; C3, 7% vs. 29%,
not statistically analyzed because of small case numbers). All cellular I and IV
versus all presumptive antibody–mediated II, III, V, and VI rejection groups:
PTCL-C (49% vs. 61%, difference not significant). Significantly less PTCL-C3 in
cellular (21%) versus presumptive antibody–mediated rejection (50%, P<0.01).
Calcineurin inhibitor toxicity VIII versus acute I to III and chronic IV to VII
rejection: PTCL-C and C3 in 36% and 18% of biopsies, respectively, with CNI
toxicity, not significantly different from acute rejection groups I to III or chronic
inactive rejection group VII. PTCL-C was significantly more frequent in the
combined chronic active rejection groups IV to VI (73%, P<0.04; C3 not
statistically analyzed because of small case numbers). Comparative control group
IX: PTCL-C (5%) and PTCL-C3 (2%).
b. Patient-based approach: 144 patients with available data on the C4d staining profile
were grouped into diagnostic categories according to histologic findings in their
last available transplant biopsy, including historic C4d staining results from
preceding biopsies in 48 of 144 patients. This approach accounted for possible
transient historic antibody–mediated injury/C4d positivity that could have induced
PTCL and may have been underestimated in the “biopsy-based approach” outlined
previously. Fifty-one (35%) of 144 patients showed PTCL-C, and 35 (24%) of 144
patients showed PTCL-C3 in a distribution among diagnostic categories similar to
that listed in Table 2. Seven of 51 patients with PTCL-C (C3, 3 of 35) showed no
evidence/history of C4d positivity and no evidence/history of capillaritis, that is, no
glomerulitis and no more than minimal peritubular capillaritis (grade I, data not
shown).
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Donor-specific antibodies (DSAs) were checked in 42 of 144 patients at 54 of 183 biopsy
time points (DSA positivity, 20/42 patients at 25/54 biopsy time points/samples). DSA
positivity was associated in 48% (12/25 samples) with PTCL-C and 40% (10/25) with
PTCL-C3. DSA negativity was associated in 28% (8/29) with PTCL-C and 17% (5/29) with
PTCL-C3 (all differences not significant). Eighteen (72%) of 25 DSA+ biopsies were
additionally C4d+ (PTCL-C, 9 [50%] of 18; PTCL-C3, 7 [39%] of 18). In comparison, 23
(80%) of 29 DSA− biopsies were also C4d− (PTCL-C, 5 [22%] of 23; C3, 2 [9%] of 23;
difference between DSA+/ C4d+ and DSA /C4d groups: PTCL-C, not significant; PTCL-C3,
P<0.03).
Logistic Regression
Both positivity for C4d staining and a biopsy more than 24 months after grafting
significantly increased the OR of PTCL-C and PTCL-C3.
In a subanalysis of categorical diagnoses using the control group as a reference and
adjusting for time, all diagnostic categories correlated significantly with PTCL-C and C3.
The likelihood of PTCL-C/C3 was lowest in cases with acute rejection or calcineurin
inhibitor–induced toxicity and highest in cases with mixed T-cell and presumptive antibody-
mediated chronic rejection (Table 3).
PTCL and Predictive Diagnostic Values
When PTCL-C (or subgroup C3) was present, samples were obtained more than 1 year after
transplantation in 97% of cases (C3, 100%), showed associated elevated DSAs in 60% (C3,
67%), showed C4d positivity in 52% (C3, 68%), and showed TGL in 49% (C3, 59%).
Biopsies with PTCL-C or subgroup C3 showed chronic active rejection with C4d positivity
in 37% (C3,49%), chronic active T-cell–mediated rejection in 25% (C3, 17%), acute
rejection with C4d positivity in 15% (C3, 20%), chronic inactive rejection in 8% (C3, 5%),
calcineurin inhibitor-induced toxicity in 6% (C3, 5%), acute T-cell–mediated rejection in
5% (C3, 2%), and other diagnoses (such as glomerular diseases or infections) in 4%
(C3,2%). Table 4 summarizes predictive values of PTCL-C and C3 for different rejection
categories.
DISCUSSION
Our study of native and renal transplant specimens is the largest most comprehensive
analysis of the diagnostic significance of PTCL published to date. For the first time, PTCL
categories are systematically studied in native and transplanted kidneys, results correlated
with Banff rejection categories, ORs calculated, and positive and negative diagnostic
predictive values defined. Our in-depth analysis sheds new light on the diagnostic
significance of PTCL and highlights strategies for best interpretation during the evaluation
of allograft biopsies.
PTCL is not a new observation. It was reported by Zollinger et al. (17) nearly 40 years ago
and subsequently further studied by Monga et al. (3, 4, 13), Ivanyi et al. (2, 6, 18, 19), and
Drachenberg et al. (5). With the recent growing interest in antibody-mediated rejection, the
diagnostic significance of PTCL has been re-evaluated. Some authors reported a tight
association between severe PTCL and DSA/C4d positivity in late graft biopsies (2, 9, 12, 14,
20–22). PTCL is part of the “Banff definition” of chronic antibody-mediated rejection (23).
Unfortunately, nearly all studies on PTCL thus far have been limited (2, 3, 7–12), and
diagnostically useful threshold levels as well as the overall significance of PTCL still remain
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undetermined. For example, Banff ‘05 and ‘07 reports place emphasis on PTCL for the
diagnosis of chronic antibody-mediated rejection without providing strict scoring guidelines
(23, 24). The Edmonton group analyzing the impact of antibodies on kidney transplants
chose to score findings in the single most affected capillary (25) and, in one recent
publication, considered cases with greater than 5 PTCL as “positive” (26). Regele and
colleagues (9) using 5 or more circumferential PTCL layers in three capillaries as threshold
in a selected cohort of late allograft biopsies found a strong association with the deposition
of C4d and presumed antibody induced graft injury. In 2007, Lerut and colleagues (27)
followed the original approach of Ivanyi et al. (2, 6, 18, 19) (severe PTCL defined by ≥5
circumferential PTCL layers in 3 capillaries or ≥7 layers in 1 capillary) and failed to find a
significant association between DSAs and PTCL. Thus the question, “what can the detection
of PTCL really tell us?” remains.
We formed scoring categories based on previous reports (5, 6). We focused on “the Ivanyi”
severe PTCL group (termed in our analysis PTCL-C1–3) and additionally studied a new
subgroup of very severe PTCL (named subgroup C3 in this report). We showed that PTCL
developed in the setting of extended endothelial activation and represented a general
mechanism of tissue remodeling that spanned from minimal to marked. In our cohort,
PTCL, including the severe and very severe subgroups, did not correlate with patient age,
race, or gender, and it was not pathognomonic for any specific type of kidney disease/
rejection type. In native kidney specimens, chronic injury with sclerosis was significantly
associated with PTCL-C1–3 but not with the very severe PTCL subgroup C3. The degree of
multilamination was dependent on the type and duration of the underlying endothelial
stimulus. Thus, the most severe forms of PTCL were overall rare in native kidneys and
significantly more common in renal allografts after year 1, in particular the very severe
PTCL subgroup C3. This observation, to us, suggests that the PTCL subgroup C3 is an
important diagnostic category to consider in the evaluation of transplant biopsies. For the
first time, we showed that PTCL-C1–3 and subgroup C3 was seen in acute rejection
episodes, both T cell and antibody mediated, and in cases with calcineurin inhibitor toxicity.
Logistic regression identified graft age, a positive C4d staining status, the presence of
transplant glomerulopathy, calcineurin inhibitor toxicity, or acute rejection as “mild risk
factors” for severe capillary lamination. The prevalence of PTCL-C/C3 and ORs increased
with chronic injury, such as chronic T-cell rejection (Banff category 4). The group with
“greatest protracted capillary injury,” that is, cases with mixed chronic T-cell and concurrent
presumptive chronic antibody-mediated (Banff category 2) rejection, carried by far the
highest OR of very severe PTCL subgroup C3. In general, C4d positivity or the presence of
DSAs served as a “PTCL enhancer.” In our study cohort, C4d+ biopsies with confirmed
concurrent elevated DSA titers showed PTCL-C1–3 and PTCL subgroup C3 in overall 50%
and 39% of cases, respectively. In comparison, biopsies without evidence of circulating
DSAs, that is, C4d− and DSA−, showed PTCL-C1–3 and PTCL subgroup C3 in overall 22%
and in 9% of cases, respectively. Thus, “antibodies”, while not the only promoters, are
definitely strong promoters of PTCL and, in particular, PTCL subgroup C3. This effect
becomes most apparent in the setting of chronic allograft injury (Fig. 1), although the
prevalence of PTCL-C1–3 or subgroup C3—even in chronic antibody-mediated rejection—
never reached 100%. Considering our findings, it is not surprising that neither severe PTCL-
C1–3 nor the very severe PTCL subgroup C3 showed high sensitivities for various types of
rejection. Overall, we found PTCL subgroup C3 to be most useful in the evaluation of
transplant biopsies because only PTCL subgroup C3 correlated with chronic tissue injury
and capillaritis in allografts, and it presented with the best positive and negative predictive
values for (chronic) antibody-induced graft injury. Based on our overall study approach, our
interpretations do not seem to be significantly limited by the relatively small number of
patients with known DSA status.
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We conclude that EM and the search for very severe PTCL subgroup C3 is a useful adjunct
method in the evaluation of allograft biopsies, in particular after transplantation year 1. We
suggest using stricter threshold levels, that is, our PTCL subgroup C3 criteria, for diagnostic
purposes. In order to properly identify representative cortical zones without severe scarring
or necrosis, it is important to initially scan cases at low magnification (×2500). In
appropriate regions, 15–20 peritubular capillaries should be further examined at higher
magnification (× 5000–7000), and the three most affected capillaries should be used for
scoring, that is, a “three-step EM approach.” The presence of very severe PTCL subgroup
C3 is helpful with establishing a diagnosis of rejection-induced injury, possibly antibody
mediated and chronic. The absence of very severe PTCL subgroup C3 is a strong indicator
to exclude any (chronic) antibody-mediated rejection. Thus, recommendations on the
interpretation of very severe PTCL in the evaluation of allograft biopsies should include
information on both positive and negative predictive values. Per case, the EM examination
of PTCL takes approximately 5 to 10 min, and the subsequent analysis of selected images
including PTCL counts approximately 3 min. We believe that scoring attempts based on the
evaluation of less than 3 capillaries with less than 5–7 circumferential basement membrane
layers each are ill suited for diagnostic purposes, in particular, to evaluate potential antibody
induced injury.
Some previous reports suggested that transplant glomerulopathy and PTCL are concurrent
findings (21, 24). However, we observed that overall, only half of our cases with PTCL-C or
C3 also showed TGL. In particular, severe PTCL was uncommon in biopsies with Banff cg
scores 1 and 2, especially in C4d− cases. This finding is in contrast to a previous report (25).
Our data illustrate that the pathogenesis of capillary wall remodeling in different tissue
compartments is complex and not uniform, even in the presence of antibodies.
For the first time, we report that severe and very severe PTCL can not only be seen in
chronic allograft injury, including chronic T-cell–mediated rejection, but also in Banff acute
rejection episodes. This finding raises an additional question: What morphologic changes
should be used to define chronic rejection? Considering our findings and other recently
reported ultrastructural observations (21, 28), currently used light microscopic criteria to
mark chronic rejection may be too restrictive, and it seems that EM can help to identify early
chronic changes that could potentially benefit from therapy and might even be reversible in
some cases (28). Thus, EM studies could help us to revisit current Banff rejection categories.
MATERIALS AND METHODS
This retrospective study was approved by the University of North Carolina institutional
review board. Between May 2004 and February 2009, 547 diagnostic renal biopsies and
nephrectomy specimens from 507 patients were analyzed: 357 biopsies and 3 nephrectomies
from 360 patients with native kidney diseases; 178 allograft biopsies and 9 transplant
nephrectomies from 147 transplant recipients. Selected clinical data were obtained from the
hospital database: age, sex, race, circulating donor-specific antibodies at time of biopsy from
a subgroup of patients, and allograft biopsy diagnoses before May 2004.
Histologic Analysis
All biopsies sufficed for rendering a diagnosis. Sections were prepared for light,
immunofluorescence, and EM according to standard protocols. C4d accumulation was
evaluated using Banff ‘07 criteria (by immunofluorescence staining in 176 and
immunohistochemistry in 7 cases) (23); four cases without C4d data were excluded from
some analyses. Diffuse and focal C4d staining was grouped as “positive” in some analyses.
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Lesions were categorized according to published criteria (15,16,23, 29–32). Thrombotic
microangiopathy (mainly seen in malignant hypertension and atypical hemolytic-uremic
syndromes) were grouped into early exudative and late remodeling phases. Light
microscopic scoring was only performed in biopsies containing 10 or more glomeruli or
adequate vascular cross sections. In allografts, scoring focused on interstitial fibrosis/tubular
atrophy, global glomerulosclerosis, peritubular capillaritis, and TGL (see following).
1. Light microscopy
Interstitial fibrosis/tubular atrophy, arteriosclerosis, arteriolosclerosis, interstitial
inflammation, and peritubular capillaritis were graded according to Banff
definitions (grade I in our system combines corresponding Banff lesion scores 0
and 1; grade II in our system combines corresponding Banff lesion scores 2 and 3)
(23, 32, 33). Transplant glomerulopathy was graded as segmental (combined
Banff’97 cgl and cg2 scores) or global (Banff’97 cg3 score) (32). Global
glomerulosclerosis was graded as grade I (≤30%); grade II (>30% of glomeruli).
2. Electron microscopy
a. PTCL: Cases were initially scanned at low magnification (×2500) to find
representative cortical regions without severe scarring, necrosis, or marked
tubular atrophy. In these regions, 15–20 capillaries were examined at
higher magnification (× 5000–6300) to identify the three most affected
vessels that formed the basis for PTCL scoring modeled after previous
reports (5, 6). Segmental PTCL was defined as two or more basement
membrane layers/laminations involving less than 50% of a capillary
circumference. Circumferential PTCL showed two or more laminations
involving 50% or more of a capillary circumference. Basement membrane
layers were counted by two observers. Consensus results formed the basis
of the PTCL subgrouping.
Group A, mild PTCL: three circumferential basement membrane layers or
less in all three capillaries (Fig. 2) or any degree of segmental lamination.
Group B, moderate PTCL: four or more but less than seven
circumferential layers in one or two capillaries. Any segmental or four
circumferential laminations or less in the remaining one or two capillaries
(Fig. 2).
Group C, severe PTCL subgroup C1: five or six circumferential layers in
three capillaries. Subgroup C2: seven circumferential layers or more in
one capillary, five circumferential layers or less or any degree of
segmental layering in the second capillary, and any layering in the third
capillary. Subgroup C3: seven circumferential layers or more (Fig. 2) in
one capillary and five circumferential layers or more in the remaining two
capillaries.
The three capillaries used for PTCL scoring were additionally analyzed.
b. “Ultrastructural capillaritis,” one inflammatory cell or more in one
capillary or more.
c. “Ultrastructural endothelial cell activation,” two endothelial cell nuclei or
more in one peritubular capillary cross section or more.
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Cross-Matching and DSA Determination
One hundred forty-six of 147 patients received ABO-compatible transplants; all patients
were transplanted after a negative T-cell and B-cell flow cytometry crossmatch.
In selected cases, clinical suspicion of antibody-mediated rejection triggered testing for
DSAs (42 patients at 54 biopsy time points). Alloantibody profiles were assessed by solid
phase testing with flow cytometry or multiplex bead arrays. Sera were screened for class I
and II human leukocyte antigen antibodies, and positive cases were further analyzed to
determine antibody specificities.
Data Analysis
Data analysis primarily focused on PTCL group C (composed of the three subgroups 1–3)
and PTCL subgroup C3 (C3 with most pronounced basement membrane abnormalities).
Cases were primarily categorized according to Banff’07 guidelines. C4d positivity resulted
in a diagnosis of “presumptive antibody-mediated rejection” (23). Cases grouped as
calcineurin inhibitor–induced toxicity by definition lacked evidence of rejection. In the
transplant cohort, a comparative control group was defined: specimens with recurrent/de-
novo renal disease, acute tubular injury, arterionephrosclerosis, infections, diabetes mellitus,
but without signs of rejection or calcineurin inhibitor–induced toxicity. A subanalysis was
performed on biopsies from patients with known DSA status.
Differences were analyzed by Fisher exact, Wilcoxon, and chi-square tests. To determine the
relative contribution of various histologic findings to PTCL, logistic regression models were
used with PTCL-group C as the outcome of interest. Interobserver agreement was
determined by Cohen κ statistics.
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Schematic of changes associated with severe and very severe peritubular capillary basement
membrane multilaminations (PTCL). Marked chronic kidney injury, such as seen in diabetes
mellitus, can promote severe (so-called PTCL-C(1–3)) and very severe (so-called “PTCL-
subgroup C3” in a minority of cases (listed as %). In allografts or native kidneys disease
conditions with capillary injury can promote PTCL and the overall rate of severe basement
membrane multilaminations increases. Very severe, so-called PTCL-subgroup C3, is
primarily seen in renal allografts with protracted, often antibody induced injury that serves
as general “PTCL amplifier”.
Liapis et al. Page 12














Electron microscopy illustrating PTCL using uranyl acetate stains. A, Normal peritubular
capillary with one circumferential basement membrane layer (original magnification 6300).
B, Segmental peritubular capillary multilayering (original magnification 6300). C, Moderate
circumferential peritubular capillary multilayering with four layers (original magnification
8000). D, Severe circumferential peritubular capillary multilayering. The consensus PTCL
score for this case was 12 layers (original magnification 6300).
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TABLE 1
Transplant biopsy specimens: PTCL groups C (1–3) and PTCL Subgroup C3 in histologic categoriesa
Group C (1–3) Subgroup C3
Histologic Findings n C in total n, % C3/C (1–3) Subgroup C3 in group C (1–3), %
Tubulointerstitial rejectiona (n=70) 38 54b 24/38 63b
Transplant endarteritisa (n=8) 3 38b 2/3 67
Transplant glomerulitisa (n=16) 12 75b 7/12 58b
All transplant glomerulopathya (n=50) 32 64 24/32 75
Global (n=38) 29 76b 22/29 76b
Segmental (n=12) 3 25 2/3 67
All transplant sclerosing vasculopathya (n=45) 30 67b 18/30 60b
Active with endarteritis (n=22) 16 73b 12/16 75b
Inactive without endarteritis (n=23) 14 61b 6/14 43b
Calcineurin inhibitor toxicity (n=11) 4 36b 2/4 50 (NS)
All comparative transplant control group (n=64) 3 5 1/3 33
Others (n=48) 1 2 0/1 0
Recurrence/de novo diseases (n=11) 0 0 0/0 0
Diabetes mellitus (n=5) 2 40 1/2 50
All C4d+a (n=56) 34 61b 28/34 82b
C4d+ diffuse (n=40) 27 68b 23/27 85b
C4d+ focal (n=16) 7 44b 5/7 71b
All C4d−a (n=127) 31 24 13/31 41
All biopsies ≤1 yra (n=38) 2 5 0/2 0
Tubulointerstitial rejection (n=8) 0 0 0/0 0
Transplant endarteritis without (n=2) 0 0 0/0 0
Transplant glomerulitis (n=l) 0 0 0/0 0
Transplant glomerulopathy (n=2) 0 0 0/0 0
Transplant sclerosing vasculopathy (n=3) 1 33 0/1 0
All C4d+ (n=9) 0 0 0/0 0
C4d+ diffuse (n=5) 0 0 0/0 0
C4d+ focal (n=4) 0 0 0/0 0
All C4d−(n=29) 2 7 0/2 0
All biopsies >1 yra (n=145) 63 43 41/63 65
Tubulointerstitial rejection (n=62) 38 61 24/38 63
Transplant endarteritis (n=6) 3 50 2/3 67
Transplant glomerulitis (n=15) 12 80 7/12 58
Transplant glomerulopathy (n=48) 32 67 24/32 75
Transplant sclerosing vasculopathy (n=42) 29 69 18/29 62
All C4d+ (n=47) 34 72 28/34 82
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Group C (1–3) Subgroup C3
Histologic Findings n C in total n, % C3/C (1–3) Subgroup C3 in group C (1–3), %
C4d+ diffuse (n=35) 27 77 23/27 85
C4d+ focal (n=12) 7 58 5/7 71
All C4d− (n=98) 29 30 15/29 52
a
Cases can show more than one rejection-associated histologic change.
b
Comparison of PTCL-C1–3 and PTCL Subgroup C3 with transplant control group, P<0.05.
Specimens in the “comparative control group” and in the “calcineurin inhibitor toxic group” lack per definition any evidence of rejection or C4d
positivity. No analysis performed in some groups because of either overlap with cases in control category or small case numbers.
PTCL, peritubular capillary basement membrane multilamination; NS, not significant.
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